

ASX ANNOUNCEMENT

12 May 2026

Probiotal SpA exclusive supply agreement extended to 2028

Highlights

- *Biome* has executed a two-year extension to its existing exclusive supply agreement with Probiotal SpA, one of *Biome*'s key supply chain partners since incorporation in 2018
- Extension replaces the previous agreement, which was due to expire in June 2026, and now runs through 2028 on existing terms
- Extension provides *Biome* and Probiotal with the platform to continue their long-standing relationship as *Biome* scales its international footprint
- *Biome*'s Australian manufacturing onshoring program, a *Biome*-led initiative, continues to progress and is well underway

Biome Australia Limited (ASX: BIO) (*Biome* or the *Company*) is pleased to announce that it has executed a two-year extension to its existing exclusive supply agreement with Probiotal SpA. Probiotal has been a strain partner of *Biome* since the *Company* was incorporated in 2018.

Two-year extension on existing terms

The previous exclusive supply agreement was due to expire in June 2026. The executed extension takes the agreement through 2028 on the existing commercial terms.

The extension provides *Biome* and Probiotal with the runway to continue executing on existing arrangements as *Biome* scales its international footprint across Australia, Canada, the United Kingdom, Ireland and New Zealand.

Long-standing partnership in *Biome*'s broader supply chain strategy

Probiotal has been one of *Biome*'s most important strategic partners since the *Company* was founded, and the two businesses share a long-standing working relationship. *Biome* and Probiotal intend to continue developing the partnership in step with *Biome*'s growth profile.

In parallel, *Biome*'s Australian manufacturing onshoring program, a *Biome*-led initiative, continues to progress and is well underway. The *Company* will provide a further update on Australian manufacturing within calendar 2026.

Commentary

Blair Vega Norfolk, Founder and Managing Director of Biome Australia, said:

"Probiotal has been one of our most important strategic partners since the Company was founded. This two-year extension on existing terms gives both businesses the certainty to continue executing as Biome scales internationally, and we look forward to continuing to develop the partnership alongside the ongoing investment we are making in Australian manufacturing capability."

–ENDS–

Approved for release by the Biome Australia board of directors.

Investor Hub

Biome has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub at <https://investorhub.biomeaustralia.com/>.

About Biome Australia Limited

Biome Australia develops, licences, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. *Biome* aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, *Biome* distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, *Biome* produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: *Activated Probiotics*®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, *Activated Probiotics* and *Activated Therapeutics* help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, *Biome* is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com


Investor Relations



Biome Australia Limited
192-194 Johnston Street
Collingwood VIC 3066

+61 3 9017 5800
support@activated.co
biomeaustralia.com

ASX:BIO
ACN 627 364 014



Lauren Dwyer
corporate@biomeaustralia.com
(03) 9017 5800

Forward Looking Statements

This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Patent applications are subject to examination processes and grant is not guaranteed. Clinical trial results cannot be predicted and may not support commercial development. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

